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Wiltrud Richter3 and Tobias Gotterbarm1*Abstract
Background: Bone marrow-derived mesenchymal stromal cells (BM-MSCs) play an important role in modern tissue
engineering, while distinct variations of culture media compositions and supplements have been reported. Because
MSCs are heterogeneous regarding their regenerative potential and their surface markers, these parameters were
compared in four widely used culture media compositions.
Methods: MSCs were isolated from bone marrow and expanded in four established cell culture media. MSC yield/1000
MNCs, passage time and growth index were observed. In P4, typical MSC surface markers were analysed by fluorescence
cytometry. Additionally, chondrogenic, adipogenic and osteogenic differentiation potential were evaluated.
Results: Growth index and P0 cell yield varied importantly between the media. The different expansion media had a
significant influence on the expression of CD10, CD90, CD105, CD140b CD146 and STRO-1. While no significant
differences were observed regarding osteogenic and adipogenic differentiation, chondrogenic differentiation was
superior in medium A as reflected by GAG/DNA content.
Conclusions: The choice of expansion medium can have a significant influence on growth, differentiation
potential and surface marker expression of mesenchymal stromal cells, which is of fundamental importance
for tissue engineering procedures.
Keywords: Mesenchymal stromal cells, Expansion media, Surface markers, Osteogenic differentiation,
Chondrogenic differentiation, Adipogenic differentiationBackground
Since their recognition in the 1960s and 70s [1,2], mes-
enchymal stem or stromal cells (MSC) are considered
one of the most promising targets for regenerative medi-
cine. MSC were first isolated from animal bone marrow
(BM) [3], but a variety of tissues in humans, such as adi-
pose tissue [4], cord blood [5], peripheral blood [6] and
connective tissues [7] have also proven to be a yielding
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reproduction in any medium, provided the orThe potency of human MSC (hMSC) to differentiate into
various cell lines, such as fibroblasts, myofibroblasts, osteo-
blasts, chondroblasts and adipocytes [8,9] put these cells
into the current focus of tissue engineering, particularly in
the fields of bone [10,11] and cartilage [12,13] regener-
ation, but also in myocardial infarction [14,15].
Minimal criteria for MSC have been postulated by the
International Society for Cellular Therapy [16]: they
must express CD105, CD73 and CD90 and lack expres-
sion of hematopoietic markers such as CD45, CD34,
CD14 and CD11b. In addition, MSC must be capable of
differentiating into fibroblasts, osteoblasts, adipocytes
and chondroblasts under specific in vitro conditions.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion techniques and expansion conditions for MSCs
[12,17-19]. Basal culture media and supplements have
become a considerable market with the growth of mes-
enchymal stromal cell research. Up to this day, only little
attention was paid to the distinct variations of culture
media, growth factors and other supplements used in
this field of research.
Yet there is increasing evidence that the choice of cul-
ture media has an important influence on the biological
properties of MSCs [9,19-21]. Besides, recent studies re-
port that bone marrow derived MSC may consist of sev-
eral distinct subpopulations with diverse regenerative
potential [22,23]. However, the properties of these sub-
populations and their usability in tissue engineering are
only marginally explored.
The aim of this study therefore was to analyse the influ-
ence of four different widely used culture media on growth
parameters and surface marker distribution of human BM-
MSCs. Rather than determining the influence of single cul-
ture additives, actual media compositions that were in use
in our laboratory were compared to each other with the
main focus on the impact on surface marker distribution.
Methods
Bone marrow donors
Human MSCs were isolated from bone marrow of 12
donors (mean age 33 ± 21.6 years, 6 female, 6 male).
Bone marrow aspiration was performed in the tibia (n = 2),
femur (n = 2) or the iliac crest (n = 8) within the framework
of total joint arthroplasty or osteotomy. The study protocol
had been approved by the ethics committee of the Uni-
versity of Heidelberg, Germany. All patients provided
informed consent according to the latest version of the
Helsinki Declaration.
Mesenchymal stromal cells (MSCs)
Bone marrow was intraoperatively diluted to 1:1 isotonic
saline solution (B. Braun Melsungen, Germany) with
5000 I.E. of heparine (ratiopharm, Ulm, Germany).
Mononuclear cells (MNCs) were isolated from these bone
marrow samples by Ficoll Paque plus (GE Healthcare,
Uppsala, Sweden) gradient centrifugation. After Ficoll sep-
aration, the cells of all donors were distributed into four
equal samples and resuspended in different cell culture
media as described below at a density of 5 × 105 cells/cm2
(equals 2.5 × 106 cells/ml) in T75 cm2 cell culture flasks
(Nunc, Roskilde, Denmark). MSCs were then cultured
under the exact same conditions, at 37°C with 6% CO2 in
a humidified thermostat, except for the use of four differ-
ent culture media:
1. Dulbecco’s modified Eagle’s medium low glucose
(DMEM-LG, Invitrogen, Karlsruhe, Germany) with 10%fetal calf serum (FCS, Biochrom, Berlin, Germany) and 1%
penicilline/streptomycine (Invitrogen, Karlsruhe, Germany)
(referred to as medium A).
2. Alpha minimum essential medium (αMEM) with
L-glutamine with 10% fetal calf serum (FCS, Biochrom,
Berlin, Germany) and 1% penicilline/streptomycine
(Invitrogen, Karlsruhe, Germany) (medium B).
3. A variation of “Verfaillie” medium (medium C) [18],
consisting of 547.5 ml Dulbecco’s modified Eagle’s medium
high glucose (DMEM-HG, Invitrogen, Karlsruhe, Germany)
and L-glutamine (Invitrogen, Karlsruhe, Germany), 40 ml
MCDB (Sigma-Aldrich, Steinheim, Germany), 20 ml
FCS (Biochrom, Berlin, Germany), 10 ml penicilline/
streptomycine (Invitrogen, Karlsruhe, Germany), 20 ml
IST (Sigma-Aldrich, Steinheim, Germany), 2 ml dexa-
methasone (Sigma-Aldrich, Steinheim, Germany), 500 μl
ascorbic acid (Sigma-Aldrich, Steinheim, Germany),
10 ng/ml PDGF-BB (Miltenyi Biotec, Bergisch Gladbach,
Germany), 10 ng/ml EGF (Miltenyi Biotec, Bergisch
Gladbach, Germany).
4. A variation of “Bernese chondrocyte medium”
(medium D) [24,25], consisting of Dulbecco’s modi-
fied Eagle’s medium F12 + L-glutamine (Invitrogen,
Karlsruhe, Germany), 1% penicilline/streptomycine (Invit-
rogen, Karlsruhe, Germany), 10% FCS (Biochrom, Berlin,
Germany), 10 μl/50 ml TGF-ß1 (Acris, Herford, Germany),
2.5 μl/50 ml FGF-2 (Acris, Herford, Germany).
After 24 hours, non-adherent cells were discarded;
afterwards, medium replacement was carried out every
72 hours.
Cells were inspected daily for confluence by polarisa-
tion microscopy. When reaching 80% confluence, cells
were detached by incubation with trypsine (Biochrom,
Berlin, Germany), harvested and washed with the corre-
sponding complete medium. Cells were counted in tripli-
cates after staining with trypan blue 0.4% (Sigma-Aldrich,
Steinheim, Germany). MSCs were then resuspended and
further cultured according to the protocol detailed above.
The end of this first passage was defined as P1. The proced-
ure was repeated until the end of the fourth passage (P4).
Growth parameters
Cells were counted before and after Ficoll separation,
and after each passage in triplicates as detailed above,
and passage time was analyzed. The following parame-
ters were then calculated: MSC yield in P0, P1, P2, P3
and P4 per 1000 BM-MNCs and MSC growth index
(MSCs before passage x/MSCs after passage x) and com-
pared between the media.
Chondrogenic differentiation
After P4, MSCs were harvested with trypsine/EDTA as
described above and centrifuged into pellets containing
5 × 105 cells (n = 6 donors per group, n = 3-5 pellets per
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chondrogenic medium consisting of 286 ml DMEM HG
(Invitrogen, Karlsruhe, Germany), 150 μl transferrin
10 mg/ml (Sigma-Aldrich, Steinheim, Germany), 1 μl
sodium selenite 100 μg/ml (Sigma-Aldrich, Steinheim,
Germany), 3 ml Sodium pyruvate 350 mM (Sigma-
Aldrich, Steinheim, Germany), 5 ml BSA 7.5% (Invitrogen,
Karlsruhe, Germany), 3 ml P/S (Invitrogen, Karlsruhe,
Germany), supplemented with 50 μl dexamethasone/5 ml
(Sigma-Aldrich, Steinheim, Germany), 5 μl ascorbic
acid/5 ml (Sigma-Aldrich, Steinheim, Germany), 5 μl
TGF-ß1/5 ml (Acris, Herford, Germany), 6.9 μl insuline
glargin/5 ml (Sanofi Aventis, Frankfurt, Germany).
Medium was changed three times a week. Chondrogenic
differentiation potential was evaluated by a glycos-
aminoglycan (GAG) assay (n = 2 per donor). The pel-
lets were digested with pepsin solution overnight.
1,9-dimethyl-methylene blue (dye content 80%, Sigma-
Aldrich, Steinheim, Germany) was used for staining of gly-
cosaminoglycans. Measurements of absorption were
performed at 530 nm and compared to a chondroitin
4-sulfate standard (Sigma-Aldrich, Steinheim, Germany).
DNA content was measured with Quant iT ds Pico
Green DNA Assay Kit (Invitrogen, Karlsruhe, Germany)
according to manufacturers’ protocols.
In addition, the remaining pellets were fixed in 4%
paraformaldehyde and cut into 5 μm sections for hist-
ology and immunohistochemistry. The sections were ei-
ther stained with 1% alcian blue (Chroma, Muenster,
Germany) and counterstained with fast red (Sigma-
Aldrich, Steinheim, Germany), SafraninO/Fast Green
(Sigma-Aldrich, Steinheim, Germany) or used for im-
munohistochemistry. Collagen I and Collagen II staining
was performed by pre-treating the sections with 2 mg/ml
hyaluronidase (Merck, Darmstadt, Germany) and 1 mg/ml
pronase (Roche Diagnostics, Penzberg, Germany). The sec-
tions were then subjected to PBS containing 5% BSA in
order to block unspecific background and incubated with a
monoclonal mouse anti-human collagen type or II anti-
body (ICN Biomedicals, Aurora, OH) in PBS containing
1% BSA. Reactivity to the antibodies was detected by ap-
plying a biotinylated goat anti-mouse secondary antibody
(Dianova, Hamburg, Germany), streptavidin-alkaline phos-
phatase (Dako, Hamburg, Germany), and fast red (Sigma-
Aldrich, Steinheim, Germany).
Osteogenic differentiation
After passage 4, MSCs were harvested with trypsin/
EDTA as described above and 35,000 cells per well
were seeded in 24 well plates (Nunc, Roskilde, Denmark)
containing osteogenic induction medium which con-
sisted of DMEM high glucose (Invitrogen, Karlsruhe,
Germany), 10% FCS (Biochrom, Berlin, Germany), 0.1 mM
dexamethasone (Sigma-Aldrich, Steinheim, Germany),0.17 mM ascorbic acid 2-phosphate (Sigma-Aldrich,
Steinheim, Germany), 10 mM β-glycerophosphate (Sigma-
Aldrich, Steinheim, Germany) and 1% penicilline/
streptomycine (Biochrom, Berlin, Germany).
At day 21, osteogenesis was quantified by alkaline
phosphatase assay according to standard protocols.
Briefly, MSCs were lysed in 0.5 ml 1% Triton X-100
(Sigma-Aldrich, Steinheim, Germany). 100 ml lysate were
incubated with 100 ml of 1 mg/ml p-nitrophenylphosphate
in ALP-buffer (0.1 M glycine, 1 mM MgCl2, 1 mM ZnCl2,
pH 10.4). The substrate turnover was then measured at
405/490 nm using an MRX ELISA reader (Dynatech
Laboratories, Stuttgart, Germany). Results were standard-
ized to lysate protein content using a Micro BCA Protein
Assay Kit (Pierce, Rockford, USA) according to manufac-
turers’ instructions.
In addition, calcium deposition was quantified by
0.5% Alizarin Red S staining (Chroma, Münster, Germany)
according to standard protocols and quantified at 570 nm.
The results were standardized to whole protein content as
described above.
Adipogenic differentiation
After passage 4, MSCs were harvested with trypsin/
EDTA as described above and 35,000 cells per well were
seeded in 24 well plates (Nunc, Roskilde, Denmark)
containing adipogenic induction medium, consisting of
DMEM high glucose (Invitrogen, Karlsruhe, Germany),
10% FCS (Biochrom, Berlin, Germany), 1 mM dexa-
methasone (Sigma-Aldrich, Steinheim, Germany), 0.2 mM
indomethacine (Sigma-Aldrich, Steinheim, Germany),
0.5 mM isobutyl methylxanthine (Sigma-Aldrich, Steinheim,
Germany), 0.01 mg/ml insulin glargin (Sanofi-Aventis,
Frankfurt, Germany) and 1% penicilline/streptomycine
(Biochrom, Berlin, Germany).
At day 21 the cells were fixed with 4% paraformalde-
hyde and stained with 0.3% Oil Red O solution (Chroma,
Münster, Germany) to quantify differentiation into adipo-
cyte. Re-extraction of the dye was performed with 60% iso-
propanol and the optical density was measured at 490 nm.
Flow cytometry analysis
MSCs were detached with trypsine as described above,
washed in whole medium and resuspended in phosphate
buffered saline with 0.5% FCS and 2 mM EDTA.
The following anti-human antibodies were used in the
experiments: CD105 PE mouse IgG1, CD133 mouse
IgG1 (Miltenyi Biotec, Bergisch Glattbach, Germany),
CD10 FITC mouse IgG1, CD13 PE mouse IgG1, CD14
FITC mouse IgG1, CD34 PE mouse IgG1, CD44 FITC
mouse IgG2b, CD45 FITC mouse IgG1, CD49a PE mouse
IgG1, CD90 FITC mouse IgG1, CD140b PE mouse IgG2a
CD146 PE mouse IgG1, CD166 PE mouse IgG1, CD271
mouse IgG1 (BD Biosciences, Heidelberg, Germany),
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PE (Dako, Glostrup, Denmark), for MSC analysis. STRO-1
mouse IgM (R +D Systems, Wiesbaden, Germany) was la-
beled with a secondary goat anti-mouse FITC antibody
(Dako, Glostrup, Denmark). Isotype matched control anti-
bodies (IgG1 FITC and PE, IgG2a FITC and PE, IG2b
FITC, all Dako, Glostrup, Denmark) were used for assess-
ment of background fluorescence.
One-color and two color cytometry was performed
using a FACS ScanW analyser (BD Biosciences, San Jose,
USA) and the Cellquest ProW Software (BD Biosciences,
San Jose, USA). Positive fluorescence was defined as any
event above the background fluorescence, which was de-
fined by a histogram cut-off where 99.5% of the events
in isotype antibody labeled cells were considered nega-
tive. All results regarding flow cytometry are displayed
as % positive cells.
Statistical analysis
Statistical analysis was performed using the SPSS com-
puter software (SPSS Inc. Released 2009. PASW Statis-
tics for Windows, Version 18.0. Chicago: SPSS Inc.). A
three steps testing of normal distribution was performed
for each data set: 1. Graphic display (QQ-plot, histogram
and box plot), 2. Ratio analysis, 3. Kolmorogov-Smirnov
(with Lilliefors significance correction) and Shapiro-
Wilks testing. Analyses of variance (ANOVA) followed
by Bonferroni correction were performed to compare
the results for parametric data (osteogenic differentiation
results). For non-parametric data, Friedman tests were
performed to compare the four groups, followed by
Wilcoxon tests for the comparison of two groups for
paired data (chondrogenic differentiation results). A


























































Figure 1 MSC growth parameters. Growth parameters of human bone m
composition details): medium A (n = 8), B (n = 11), C (n = 11), D (n = 8). a) N
(cells seeded/cells extracted after P1). c) P2 MSC yield per 1000 initially seefollowed by Mann–Whitney-U-tests was performed for
non-paired data (growth parameters, surface markers).
Differences were considered statistically significant for
p-values smaller 0.05. Results are displayed as means ±
standard deviation.
Results
MSC growth characteristics are strongly influenced by the
choice of expansion media
An important donor-dependency of MSC growth char-
acteristics was observed. However, there was no appar-
ent correlation between growth parameters and the age
of the donor or the site of bone marrow harvest.
The amount of MNCs in the bone marrow aspirates
ranged from 6.25x105/ml to 1.69x107/ml (mean 3.85 ±
4.9 × 106 cells/ml). Mean MSC yield per 103 BM-MNCs at
P0 was significantly higher in medium C when compared
to medium A (297.29 ± 248.21 in medium C vs. 70.31 ±
88.09 in medium A; p = 0.018) (Figure 1a). This was also
reflected by a higher cell count and earlier confluency in
light microscopy when cells cultured in medium C were
compared to the other media at the same time points
(Figure 2). Four MNC samples in medium A and D and
one in medium B and C showed no growth at all.
Cell proliferation rate differed substantially between
the media with significantly lower growth index values
for medium A, B and D compared to medium C in P1
(Figure 1b, comparison of all groups p < 0.001; 5.77 ±
4.14 for medium C vs. 2.16 ± 1.22 for medium B, 2.2 ±
1.02 for medium A, 3.9 ± 1.27 for medium C; p = 0.0033,
p = 0.0027 and p = 0.0087, respectively). In P2, no sig-
nificant differences between the media were observed
regarding the growth index (comparison of all groups

































arrow derived MSCs cultured in four different media (see Methods for




Figure 2 MSC morphology. Gross appearance of human BM-MSCs cultured in four different media after 8 days in P0, polarized light microscopy,
index 100 μm. a) medium A b) medium B c) medium C d) medium D (see Methods for media composition). While all media display a similar cell
phenotype typical for plastic adherent MSCs, MSCs cultured in medium C grew faster with earlier confluence.
Hagmann et al. BMC Musculoskeletal Disorders 2013, 14:223 Page 5 of 11
http://www.biomedcentral.com/1471-2474/14/223was significantly reduced in P2 when compared to P1
(2.35 ± 1.57 in P2 vs. 5.77 ± 4.14 in P1, p = 0.014). Interest-
ingly, this resulted in medium D showing the highest cell
yield per 1000 BM-MNCs after P2 (Figure 1c, 219.37 ±
158.32 for medium D vs. 41.14 ± 33.9 for medium A,
p < 0.001; vs. 76.54 ± 81.52 for medium B, p = 0.005;
comparison of all groups p = 0.01). No significant dif-
ferences in proliferation were observed between any
of the culture conditions tested after P2.
Passage time in P0 was significantly lower in medium C
and medium B compared to medium A (comparison of all
groups p = 0.021; 12 ± 2.13 days in medium C and 12.75 ±
2.34 days in medium B vs. 17.58 ± 5.98 in medium A,
p = 0.004 and p = 0.012, respectively). Although medium C
showed the lowest mean passage time in P1, this trend did
not reach significance (data not shown, p = 0.096). In P2,
medium C showed the fastest passage time with a signifi-
cant difference to medium B (3.91 ± 1.3 days vs. 7.25 ±
2.63 days, p < 0.001; comparison of all groups p = 0.003).
Regarding passage time, no significant differences were ob-
served after P2.
Distribution of several BM-MSCs surface markers is
dependent on expansion media
Fluorescence cytometry of MSC surface markers allowed
distinction into clearly “positive”, clearly “negative” andintermediate MSC markers (Table 1, Figure 3). In all
media, there was a strong fluorescence signal (“positive”
markers) for CD13, CD44, CD73, CD90, CD105 and
CD166 (Table 1, Figure 3). There was an important
variation of CD105 fluorescence in medium C, resulting
in a significantly lower mean fluorescence compared to
the other media (comparison of all groups p = 0.0011;
72.69 ± 20.72% in medium C vs. 98.29 ± 2.04% in
medium B, p = 0.012 and 98.79 ± 1.22% in medium D,
p = 0.015). A significantly reduced fluorescence for
CD90 was also found in medium C when compared to
medium B and medium D (comparison of all groups
p = 0.001, 91.89 ± 3.65% for medium C vs. 99.12 ± 2.24%
for medium B, p = 0.003 and 98.77 ± 1.39% for medium D;
p = 0.002, respectively). CD166 fluorescence was reduced
in medium C when compared to medium D (p = 0.026).
There was no difference between the media regarding
CD13, CD44 and CD73 fluorescence.
Low fluorescence (“negative” markers) was observed
for CD10, CD14, CD34, CD45, CD133 and CD271
(Table 1). No significant differences between the media
were observed except for CD10 fluorescence in medium C
compared to medium B (Figure 3, 26 ± 21.84% vs. 1.02 ±
1.35%, p = 0.01).
Numerous surface markers were found to be highly
donor dependent (CD49, CD140b, CD146, CD340 and
Table 1 Surface marker distribution on human bone
marrow derived mesenchymal stromal cells in four
different culture conditions
Medium A Medium B Medium C Medium D
CD10 12.954 ± 18.76 1.02 ± 1.35 26 ± 21.84 3.15 ± 3.44
CD13 95.37 ± 8.08 98.97 ± 2.03 99.83 ± 0.11 99.79 ± 0.27
CD14 0.36 ± 0.19 1.21 ± 1.28 0.47 ± 0.22 0.63 ± 0.2
CD34 0.40 ± 0.42 0.31 ± 0.25 0.32 ± 0.13 0.34 ± 0.15
CD44 94.04 ± 8 98.27 ± 1.99 96.13 ± 4.47 99.22 ± 0.6
CD45 0.342 ± 0.22 0.33 ± 0.18 0.36 ± 0.17 0.2 ± 0.16
CD49 52.03 ± 22.36 61.37 ± 18.11 45.15 ± 31.27 48.23 ± 23.98
CD73 95.572 ± 4.19 98.1 ± 1.95 97.57 ± 2.71 99.58 ± 0.26
CD90 95.25 ± 5.68 99.12 ± 2.24 91.89 ± 3.65 98.77 ± 1.39
CD105 92.32 ± 6.98 98.29 ± 2.04 72.69 ± 20.72 98.79 ± 1.22
CD133 0.57 ± 0.32 0.71 ± 1.1 0.74 ± 0.15 0.68 ± 0.61
CD140b 70.42 ± 34.91 90.51 ± 11.44 10.87 ± 15 78.12 ± 25
CD146 47.64 ± 29.68 47.64 ± 28.96 19.27 ± 28.6 84.92 ± 9.51
CD166 90.49 ± 12.19 93.21 ± 9.34 90.16 ± 8.11 99.25 ± 0.81
CD271 1.08 ± 1.03 1.8 ± 2.71 2.68 ± 2.34 2.69 ± 2.6
CD340 44.4 ± 36.34 69.96 ± 32.97 39.31 ± 24.86 68.61 ± 35.31
STRO-1 48.26 ± 32.42 78.11 ± 27.47 42.07 ± 17.09 67.07 ± 36.24
HLA-ABC 92.02 ± 17.18 97.13 ± 5.38 90.62 ± 10.83 99.76 ± 0.17
Results are displayed as means of % positive cells ± standard deviation.
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ences between the media were observed.
CD146 showed intermediate fluorescence in both
medium A and medium B with about 50% of the cells
being positive for this marker. Of all media, medium C
showed the lowest expression of CD146 while expression
was significantly higher in medium D (comparison of all
groups p = 0.005; 84.92 ± 9.51% in medium D vs. 19.27 ±
28.6% in medium C, p = 0.001; 47.64 ± 29.68 in medium A,
p = 0.003; 47.64 ± 29.96 in medium B, p = 0.016; Figure 3).
CD140b expression was also found to be significantly
lower in medium C when compared to the other media
(comparison of all groups p = 0.003; 10.87 ± 15% vs.
70.42 ± 35% in medium A, p = 0.007; 90.51 ± 11.44% in
medium B, p < 0.001; 78.12 ± 25% in medium D, p = 0.004;
Figure 3). No significant differences were observed for
CD49 and CD340 (Table 1). There was also a lower
STRO-1 expression in medium C when compared to
medium B (comparison of all groups p = 0.047; 78.11 ±
27.47% in medium B vs. 42.07 ± 17.09% in medium C,
p = 0.022; Figure 3).
The choice of expansion media affects MSC chondrogenic
differentiation potential
In all media, MSCs were able to differentiate into
chondrogenic, osteogenic and adipogenic lineages (Figures 4
and 5). No significant differences between the mediawere observed regarding osteogenic differentiation (Table 2;
Alizarin per well p = 0.455, ALP per protein p = 0.48).
Pellet size was significantly lower in medium C (0.14 ±
0.017 × 106 pixel) when compared to medium B (Figure 5a,
0.2 ± 0.033 × 106 pixel, p = 0.028) and medium D (0.27 ±
0.086 × 106 pixel, p = 0.046) and highest in medium A,
yet there was no significant difference between this
medium and the other media. Chondrogenic differen-
tiation as reflected by GAG/DNA content in the pel-
lets was highest in medium A compared to the other
media and lowest in medium C, the differences how-
ever were only significant between medium A and B
(4786.11 ± 4523.34 in medium A vs. 1424.87 ± 975.83 in
medium B, p = 0.046; Figure 5). This difference in
chondrogenic differentiation between the media was also
reflected by histology (Figure 4c), although Safranin
O/Fast Green staining revealed donor-dependent variations
in all groups.
Discussion
After less than two decades of basic research on their
proliferation and differentiation potential as well as their
immunosuppressive properties, MSCs have entered clin-
ical applications in regenerative medicine, with numerous
clinical trials in the fields of orthopaedics, hematology,
neurology, cardiology, dentistry and in the treatment of
genetical disorders [26-31]. However, there are important
variations of isolation and expansion techniques through-
out each laboratory, and reports of MSC subtypes with
distinct properties are increasing [22,23]. In this context,
our study investigated the effect of different currently
used expansion media on proliferation, differentiation,
and most importantly on surface marker distribution of
human bone marrow derived MSCs.
Our data clearly demonstrate that the choice of expan-
sion media can significantly alter not only BM-MSC
growth characteristics, but also their differentiation po-
tential such as the ability to form cartilaginous tissue
in vitro. Our data are in line with findings of previous
studies that have demonstrated inferior chondrogenic
differentiation results of MSCs expanded in a control
medium (“Verfaillie”, which corresponds to medium C
in our study) when compared to ES medium [21]. While
ALP per protein was lower in medium C than the other
media, no significant differences could be observed be-
tween the media, which on the one hand can be
explained by the high variation among the donors, and
on the other hand by a generally poor osteogenic differ-
entiation in our population. The same could be observed
for adipogenic differentiation, which was generally poor,
while variations among the donors could be observed.
The reasons for these poor differentiation results may lie
within the donors or the media preparations. However,






































































































































Figure 3 MSC surface marker distribution. Differences in surface marker distribution between of human BM-MSCs cultured in four different
media (see Table 1 for data). All results are displayed as % positive cells, means of n = 10 for medium B and C and n = 6 for medium A and D.
a) CD10, b) CD90, c) CD105, d) CD140b, e) CD146, f) STRO-1.
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tiation potential is more affected by the choice of expan-
sion media than adipogenic and osteogenic differentiation.
Our study adds to findings that quantify differences
in surface marker expression depending on the expan-
sion media applied [32]. An important study in this
field was published in 2006, revealing the impact not
only of the choice of expansion media and growth fac-
tors, but also of basic factors such as plating density
and flask manufacturer on MSC characteristics [19].
The experiments conducted in this study also revealed
that certain MSC surface markers (CD44, MAB1470,
STRO-1 and HLA-DR) showed intermediate fluores-
cence when MSCs were expanded in DMEM-HG, how-
ever without quantifying these results. Our study reveals
characteristic changes in the distribution of CD10, CD140b
and CD146 that to our best knowledge have not been pub-
lished yet, with consistent results of some more stablemarkers such as CD14, CD34 and CD45 as “negative
markers” and CD13, CD44, CD73 and CD166 as “positive”
markers [33].
Another recent study has compared four different ex-
pansion media (among these DMEM and Alpha-MEM)
and analysed adipose-tissue derived MSCs regarding
their surface markers, concluding that the expression of
CD49d, CD54 (being lowest in DMEM-KO) and CD117
was inconsistent at all passages and in all four media
while the other surface markers did not significantly
alter between the media [34]. This is not in accordance
with other studies [32] and our own findings that clearly
indicate significant differences in the expression of
CD10 (not tested in the above study), CD90, CD105,
CD140b (not tested in the above study) and CD146 (not
tested in the above study). This discrepancy could be ei-
ther due to differences in the study population or by as-
suming different characteristics of adipose-tissue derived
Medium BMedium A
Medium C Medium D
Medium A Medium B
Medium C Medium D
a b
c
Medium A Medium B Medium C Medium D
Figure 4 MSC differentiation. Influence of four expansion media on osteogenic, adipogenic and chondrogenic differentiation. Light microscopy.
a) Alizarin Red staining, index 200 μm. b) Oil Red O staining, index 200 μm. c) Safrananin O/Fast Green staining, index 500 μm. MSCs from six
















































Figure 5 MSC chondrogenic differentiation. Chondrogenic differentiation results of human BM-MSCs cultured in different media. a) Pellet size
after expansion in four different media, n = 6 donors per group, experiments conducted in duplicates. b) GAG/DNA content in pellets after
expansion in four different media, n = 6 donors per group, experiments conducted in duplicates.
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Table 2 Quantitative results of osteogenic differentiation of human bone marrow derived mesenchymal stromal cells
expanded in four different culture conditions
Medium A Medium B Medium C Medium D
μg Alizarin/well 174.96 ± 67.47 235.6 ± 98.79 242.48 ± 145.24 285.19 ± 147.29
ALP per protein 1.29 ± 1.38 1.42 ± 0.95 0.26 ± 0.42 0.76 ± 0.48
Results are displayed as means ± standard deviation.
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http://www.biomedcentral.com/1471-2474/14/223stem cells [35-37], as well as by the lower number of do-
nors (n = 3) used in the above study. Differences may
also be due to the fact that dot charts were employed to
analyse fluorescence without indication of a quantitative
threshold. In our study, histograms and a threshold of
99.5% were employed to determine positive fluorescence,
thus allowing to unmask subtle differences in fluores-
cence between the media. Another reason for the dis-
crepancy between both studies may be the use of growth
factors in two of our media, revealing an important no-
tion of how expansion media may pre-determine the se-
lection of distinct subtypes of MSC through the use of
growth factors.
Growth factors such as FGF-2 (or bFGF) and TGF-ß have
a long tradition in tissue engineering for modifying the
differentiation potential of MSCs. For instance, expansion
in the presence of FGF-2 is known to increase prolifera-
tion and chondrogenic potential of MSCs [38-40], but to
inhibit chondrogenesis when applied during chondro-
genic differentiation [41]. Application of FGF-2 to human
BM-MSCs during expansion was also found to enhance
osteogenesis and adipogenesis while suppressing neuronal
differentiation [19]. TGF-ß isoforms have been exten-
sively investigated for their potential to enhance chondro-
genesis and osteogenesis [42-44].
However, in our experiments, the highest chondrogenic
potential was obtained in a non-growth factor enhanced
medium (medium A). This controversy may be due to the
fact that differentiation was induced after P4. It is known
that the influence of growth factors diminishes with higher
passages [38]. Also, the effect cannot be extrapolated on
presence or absence of growth factors, as all tested media
contained fetal calf serum, which shows such a high vari-
ability that most groups select specifically pre-screened
lots. In our experiments, the same FCS lot was used for ex-
pansion in all four culture conditions. Three of the four
media contained 10% FCS; however, growth indices and
P0 cell yield/1000 BM-MNCs were highest in the vari-
ation of medium C containing 2% FCS, which may be
due to its growth factor content. Although the growth
factor content may also vary with different FCS lots, in
this particular setting we thus directly could demon-
strate that application of growth factors does not guar-
antee control of differentiation.
The use of these easy-to-handle bovine components
also remains controversial due to their potential safetyrisks. Although several reports have propagated easy and
efficient use of serum-free or xeno-free MSC expansion
media [17,45,46], none of these media have made it to a
wide distribution, somewhat reflecting our own experi-
ence that the use of these media is still not as practicable
as advertised.
The importance of our results lies within the notion
that the quality of MSC application may be deeply al-
tered by factors such as the choice of expansion media
and the application of growth factors. Moreover, despite
ongoing attempts of characterising MSCs and their sub-
types, these cells still represent some sort of “black box”
hiding properties that are not yet fully understood. It
would seem that this knowledge should urge scientist to
produce more reproducible results. However, apart from
a few studies, no general attempts have been made to
standardize MSC isolation and expansion procedures, al-
though it is increasingly understood that MSC may exert
different characteristics depending on which laboratory
they are cultured in [47]. The minimal MSC-defining
criteria made by the International Society for Cellular
Therapy [16] have served to narrow the term “mesenchy-
mal stem cell”, however, they lack clarification of a) what
is considered presence or absence of typical surface
markers and b) how differentiation results can be com-
pared to each other in a quantitative way, considering
that numerous reports have outlined that differentiation
properties may vary with distinct subtypes of MSCs, ex-
pansion and differentiation protocols and different tis-
sues MSCs are derived from.
Limitations
Our experiments were characterized by an important
variation of most parameters dependent on the donor of
MSCs. A limitation of this study may be that the age of
the donors was widely scattered; however, the influence
of age and comorbidities on MSC expansion and differ-
entiation is most controversially discussed [48]. In a
small series of patients, our own findings suggested that
the choice of culture media was more important than
age and comorbidity [49]. Recent reports with larger
numbers of patients reveal that proliferation character-
istics may decrease with age, but that their lineage
choice remains unaltered [48]. Although age may have
influenced our findings, by distributing MSCs of all
patients and culturing them in all four media, we were
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to the choice of culture media. However, we were able
to observe an important variation among the donors
that could not be attributed to age. The heterogeneity
of MSC preparations of different donors is a known
problem [50] that may have had an important influ-
ence on growth parameters and differentiation, but
surface markers as well.
It could be criticized that two media containing differ-
ent growth factors were examined along with two media
without growth factors and that three media contained
10% FCS while one contained 2% FCS. However, in this
study, our aim was to compare four media that are actu-
ally widely used in different laboratories rather than to
determine the influence of each component. In our
opinion, this approach creates a clearer image of how al-
legedly trivial decisions may have an influence on the
outcome of an experiment. It is clear that in the future,
experiments attributing the observed differences to sin-
gle media components will have to be conducted.
Conclusions
This study adds to several reports that emphasize on
how the choice of expansion media can influence not
only growth characteristics, but also differentiation po-
tential of MSCs. This study is in accordance with previ-
ous findings reporting differences in the expression of
typical MSC markers depending on the media applied.
We were able to detect additional MSC markers affected
by the expansion conditions that to our best knowledge
have not been reported yet. Our findings suggest that at-
tempts to further investigate how different media com-
ponents affect MSC characteristics are necessary. More
importantly, our findings are in favour of pursuing stan-
dardized protocols in MSC isolation and expansion.
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